Determinants of EV71 immunogenicity and protection against lethal challenge in a mouse model

Immunologic Research

Volumn 62, Issue 3, 2015, Pages 306-315

  Chang, Junliang ^a   Li, Jingliang ^a   Wei, Wei ^a,b   Liu, Xin ^a   Liu, Guanchen ^a   Yang, Jiaxin ^a   Zhang, Wenyan ^a   Yu, Xiao Fang ^a,b  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Enterovirus 71; HFMD; Immunogenicity; Vaccine candidate

Indexed keywords

NEUTRALIZING ANTIBODY; PROTEIN VP1; CAPSID PROTEIN; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHINA; CONTROLLED STUDY; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; GENE SEQUENCE; IMMUNOGENICITY; INFECTION CONTROL; MOLECULAR PHYLOGENY; MOUSE; NEWBORN; NONHUMAN; PHYLOGENETIC TREE; PRIORITY JOURNAL; VIRUS DETECTION; VIRUS GENOME; VIRUS ISOLATION; VIRUS STRAIN; AMINO ACID SEQUENCE; ANIMAL; CHLOROCEBUS AETHIOPS; ENTEROVIRUS A; ENTEROVIRUS INFECTIONS; GENETICS; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; MOLECULAR GENETICS; RANDOMIZATION; SEQUENCE ALIGNMENT; VERO CELL LINE; VIROLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; CERCOPITHECUS AETHIOPS; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; GENOME, VIRAL; MICE; MICE, INBRED ICR; MOLECULAR SEQUENCE DATA; RANDOM ALLOCATION; SEQUENCE ALIGNMENT; VERO CELLS; VIRAL VACCINES;

EID: 84931570822     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-015-8661-1     Document Type: Article

References (41)

1. Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129:304–9.
2. van der Sanden S, Koopmans M, Uslu G, van der Avoort H, Dutch Working Group for Clinical V. Epidemiology of enterovirus 71 in the Netherlands, 1963 to 2008. J Clin Microbiol. 2009;47:2826–33.
3. Abubakar S, Chee HY, Shafee N, Chua KB, Lam SK. Molecular detection of enteroviruses from an outbreak of hand, foot and mouth disease in Malaysia in 1997. Scand J Infect Dis. 1999;31:331–5.
4. Ang LW, Koh BK, Chan KP, Chua LT, James L, Goh KT. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001–2007. Ann Acad Med Singapore. 2009;38:106–12.
5. Chang LY. Enterovirus 71 in Taiwan. Pediatr Neonatol. 2008;49:103–12.
6. Ding NZ, Wang XM, Sun SW, Song Q, Li SN, He CQ. Appearance of mosaic enterovirus 71 in the 2008 outbreak of China. Virus Res. 2009;145:157–61.
7. Hosoya M, Kawasaki M, Sato K, et al. Genetic diversity of enterovirus 71 associated with hand, foot and mouth disease epidemics in Japan from 1983 to 2003. Pediatr Infect Dis J. 2006;25:691–4.
8. Ma E, Chan KC, Cheng P, Wong C, Chuang SK. The enterovirus 71 epidemic in 2008—public health implications for Hong Kong. Int J Infect Dis. 2010;14:e775–80.
9. Sarma N, Sarkar A, Mukherjee A, Ghosh A, Dhar S, Malakar R. Epidemic of hand, foot and mouth disease in West Bengal, India in August, 2007: a multicentric study. Indian J Dermatol. 2009;54:26–30.
10. Chan LG, Parashar UD, Lye MS, For the Outbreak Study Group, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. Clin Infect Dis. 2000;31:678–83.
11. Chen CY, Chang YC, Huang CC, Lui CC, Lee KW, Huang SC. Acute flaccid paralysis in infants and young children with enterovirus 71 infection: MR imaging findings and clinical correlates. Am J Neuroradiol. 2001;22:200–5.
12. Jiang M, Wei D, Ou WL, Li KX, Luo DZ, et al. Autopsy findings in children with hand, foot, and mouth disease. N Engl J Med. 2012;367:91–2.
13. Koroleva GA, Lukashev AN, Khudiakova LV, Mustafina AN, Lashkevich VA. Encephalomyelitis caused by enterovirus type 71 in children. Vopr Virusol. 2010;55:4–10.
14. McMinn P, Stratov I, Nagarajan L, Davis S. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis. 2001;32:236–42.
15. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9:1097–105.
16. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778–90.
17. Wang SM, Lei HY, Huang KJ, et al. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis. 2003;188:564–70.
18. Whitton JL, Cornell CT, Feuer R. Host and virus determinants of picornavirus pathogenesis and tropism. Nat Rev Microbiol. 2005;3:765–76.
19. Yan JJ, Wang JR, Liu CC, Yang HB, Su IJ. An outbreak of enterovirus 71 infection in Taiwan 1998: a comprehensive pathological, virological, and molecular study on a case of fulminant encephalitis. J Clin Virol. 2000;17:13–22.
20. Yip CC, Lau SK, Woo PC, Yuen KY. Human enterovirus 71 epidemics: what's next? Emerg Health Threats J. 2013;6:19780.
21. Chua KB, Kasri AR. Hand foot and mouth disease due to enterovirus 71 in Malaysia. Virol Sin. 2011;26:221–8.
22. Lin TY, Chang LY, Hsia SH, et al. The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. Clin Infect Dis. 2002;34(Suppl 2):S52–7.
23. Zeng M, El Khatib NF, Tu S, Ren P, Xu S, et al. Seroepidemiology of enterovirus 71 infection prior to the 2011 season in children in Shanghai. J Clin Virol. 2012;53:285–9.
24. Chia MY, Chiang PS, Chung WY, Luo ST, Lee MS. Epidemiology of enterovirus 71 infections in Taiwan. Pediatr Neonatol. 2014;55:243–9.
25. Wu WH, Kuo TC, Lin YT, et al. Molecular epidemiology of enterovirus 71 infection in the central region of Taiwan from 2002 to 2012. PLoS One. 2013;8:e83711.
26. Chen H, Zhang Y, Yang E, et al. The effect of enterovirus 71 immunization on neuropathogenesis and protein expression profiles in the thalamus of infected rhesus neonates. Virology. 2012;432:417–26.
27. Chen HL, Huang Y, Chu TW, et al. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine. 2008;26:2882–9.
28. Chong P, Hsieh SY, Liu CC, et al. Production of EV71 vaccine candidates. Hum Vaccines Immunother. 2012;8:1775–83.
29. Chung YC, Ho MS, Wu JC, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26:1855–62.
30. Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microb Infect. 2007;9:1299–306.
31. Lee MS, Tseng FC, Wang JR, Chi CY, Chong P, Su IJ. Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis. 2012;6:e1737.
32. Liang ZL, Mao QY, Wang FC, et al. Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vaccines Immunother. 2013;9:1701–5.
33. Liu JN, Wang W, Duo JY, et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine. 2010;28:7444–51.
34. Ong KC, Devi S, Cardosa MJ, Wong KT. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol. 2010;84:661–5.
35. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20:895–904.
36. Li YP, Liang ZL, Gao Q, et al. Safety and immunogenicity of a novel human enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine. 2012;30:3295–303.
37. Zhu FC, Meng FY, Li JX, Li XL, Mao QY, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024–32.
38. Reed LJM, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg. 1938;27:493–7.
39. Wang X, Zhu C, Bao W, et al. Characterization of full-length enterovirus 71 strains from severe and mild disease patients in northeastern China. PLoS One. 2012;7:e32405.
40. Li J, Chang J, Liu X, et al. Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates. J Gen Virol. 2014;95:1083–93.
41. Li L, He Y, Yang H, Zhu J, Xu X, et al. Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, People's Republic of China. J Clin Microbiol. 2005;43:3835–9.